Prognostic Value of a Joint K-PD Model With Tumor Size Dynamics and CA-125 Kinetics in Recurrent Ovarian Cancer Patients: BOLD Phase II GINECO Study.

ABSTRACT: In patients with recurrent advanced ovarian cancer, there is a need for companion tests to guide the development of innovative chemotherapy-free treatments. The modeled longitudinal CA-125 ELIMination rate constant K KELIM-B was a major prognostic factor for progression-free survival (PFS) and overall survival (OS) in recurrent advanced ovarian cancer patients treated with bevacizumab, olaparib, and durvalumab in the BOLD trial. The objective was to determine if a joint semi-mechanistic model with tumor size and CA-125 kinetics would increase KELIM-B accuracy/prognostic value. The BOLD phase II trial (NCT04015739) investigated the triplet regimen in 74 patients with recurrent platinum-sensitive/resistant advanced ovarian cancer. Two kinetic-pharmacodynamic models were developed to fit the

SUBMITTER: Carrot A 

PROVIDER: S-EPMC12358302 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature